BACKGROUND AND PURPOSE: High-dose-rate brachytherapy (HDR-BT) had been used only in combination with external beam irradiation (EBI) until our previously reported first trial of HDR-BT alone without EBI. The purpose of the current report is to evaluate the feasibility, toxicity and efficacy of this regimen, with more patient accrual and longer follow-up. MATERIAL AND METHODS: From 1995 through 2004, 111 patients with localized prostate cancer were treated with HDR-BT without EBI. Fifteen patients were considered as low-risk, 28 as intermediate-risk, and 68 as high-risk. The prescribed dose was 48 Gy/8 fractions/5 days or 54 Gy/9 fractions/5 days. Median follow-up time was 27 months (range 5-119). RESULTS: All the patients completed the treatment regimen. The 3- and 5-year PSA failure-free rates were 83% and 70%, and the local control rates 100% and 97%. The maximum toxicities observed were Grade 3 by CTCAE v3.0 (6 acute, 1 chronic). CONCLUSIONS: HDR-BT without EBI was feasible and its toxicity acceptable. Short-term tumor control was promising, even for locally advanced cases. More patient accrual and longer follow-up are needed to confirm the efficacy of this novel approach.
BACKGROUND AND PURPOSE: High-dose-rate brachytherapy (HDR-BT) had been used only in combination with external beam irradiation (EBI) until our previously reported first trial of HDR-BT alone without EBI. The purpose of the current report is to evaluate the feasibility, toxicity and efficacy of this regimen, with more patient accrual and longer follow-up. MATERIAL AND METHODS: From 1995 through 2004, 111 patients with localized prostate cancer were treated with HDR-BT without EBI. Fifteen patients were considered as low-risk, 28 as intermediate-risk, and 68 as high-risk. The prescribed dose was 48 Gy/8 fractions/5 days or 54 Gy/9 fractions/5 days. Median follow-up time was 27 months (range 5-119). RESULTS: All the patients completed the treatment regimen. The 3- and 5-year PSA failure-free rates were 83% and 70%, and the local control rates 100% and 97%. The maximum toxicities observed were Grade 3 by CTCAE v3.0 (6 acute, 1 chronic). CONCLUSIONS: HDR-BT without EBI was feasible and its toxicity acceptable. Short-term tumor control was promising, even for locally advanced cases. More patient accrual and longer follow-up are needed to confirm the efficacy of this novel approach.
Authors: Anna Rita Alitto; Luca Tagliaferri; Valentina Lancellotta; Andrea D'Aviero; Antonio Piras; Vincenzo Frascino; Francesco Catucci; Bruno Fionda; Christian Staackmann; Simonetta Saldi; Vincenzo Valentini; Gyorgy Kovacs; Cynthia Aristei; Giovanna Mantini Journal: In Vivo Date: 2020 May-Jun Impact factor: 2.155
Authors: Nicholas G Zaorsky; Brian J Davis; Paul L Nguyen; Timothy N Showalter; Peter J Hoskin; Yasuo Yoshioka; Gerard C Morton; Eric M Horwitz Journal: Nat Rev Urol Date: 2017-06-30 Impact factor: 14.432
Authors: Ryan K Berglund; Catherine M Tangen; Isaac J Powell; Bruce A Lowe; Gabriel P Haas; Peter R Carroll; Edith D Canby-Hagino; Ralph deVere White; George P Hemstreet; E David Crawford; Ian M Thompson; Eric A Klein Journal: Urology Date: 2012-03 Impact factor: 2.649
Authors: Pirus Ghadjar; Nicole Gwerder; Axel Madlung; Frank Behrensmeier; George N Thalmann; Roberto Mini; Daniel M Aebersold Journal: Strahlenther Onkol Date: 2009-11-10 Impact factor: 3.621
Authors: Markus Karl Alfred Herrmann; Tammo Gsänger; Arne Strauss; Tereza Kertesz; Hendrik A Wolff; Hans Christiansen; Hilke Vorwerk; Clemens Friedrich Hess; Andrea Hille Journal: Strahlenther Onkol Date: 2009-06-09 Impact factor: 3.621